Investment Rating - The report maintains an "Overweight" rating for the overseas pharmaceutical industry, indicating a positive outlook for the sector's performance compared to the overall market [5][10]. Core Insights - The report highlights significant developments in the pharmaceutical sector, including a licensing agreement between China National Pharmaceutical Group (Sinopharm) and Sanofi for the JAK/ROCK inhibitor, and the approval of a new indication for Innovent Biologics' BTK inhibitor in China [1][2]. - Performance forecasts for companies such as Crystal Holding and He Yu indicate substantial revenue growth, with Crystal Holding expected to achieve at least 780 million RMB in revenue for 2025, representing a year-on-year increase of approximately 193% [6][7]. Summary by Sections 1. Overseas Pharmaceuticals - Sinopharm and Sanofi have entered into an exclusive licensing agreement for the global development, production, and commercialization of the JAK/ROCK inhibitor, with potential milestone payments totaling up to 1.395 billion USD [2][7]. - Innovent Biologics' BTK inhibitor, Jiepalit (Pirtobrutinib), has received NMPA approval for a new indication in adult patients with chronic lymphocytic leukemia (CLL) who have previously undergone systemic treatment [2][7]. - Roche's BTK inhibitor Fenebrutinib has successfully met primary endpoints in a Phase III trial for relapsing multiple sclerosis, potentially becoming the first effective oral treatment for both relapsing and primary progressive forms of the disease [3][8]. 2. Performance Updates - Crystal Holding anticipates a revenue of no less than 780 million RMB in 2025, with a net profit of at least 100 million RMB, marking a turnaround from losses [6][7]. - He Yu expects to achieve 612 million RMB in revenue for 2025, reflecting a 21% year-on-year growth, with net profit projected at 55 million RMB, a 95% increase [6][7]. 3. Investment Recommendations - The report suggests focusing on innovative pharmaceutical companies with active commercialization and business development opportunities, including companies like BeiGene, Innovent Biologics, and others [10]. - It also highlights the importance of monitoring clinical progress in key pipelines for companies transitioning towards innovation [10].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中滙集團控股有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00382 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.01 USD | | 20,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.01 USD | | 20,000,000 | 本月 ...

Group 1: Industry Investment Rating - The investment rating for the overseas social services industry is positive, with a focus on the record-high visitor numbers during the Macau Spring Festival [6]. Group 2: Core Insights - The total number of inbound visitors to Macau during the Spring Festival reached 1.554 million, with an average daily visitor count of 173,000, marking a year-on-year increase of 5.5% [6][1]. - Among the inbound visitors, mainland tourists averaged 134,000 per day, reflecting a 7% year-on-year growth, while international visitors averaged nearly 7,900 per day, up by 8% [6][1]. - The hotel occupancy rate during the Spring Festival was 95.6%, with the highest rate of 99.2% recorded on the fourth day of the festival [6][1]. Group 3: Summary by Relevant Sections Overseas Pharmaceuticals - The report highlights significant developments in the pharmaceutical sector, including the announcement of clinical trial results for B7-H3 ADC by Yingensheng and the completion of Phase II trials for UBT251 by Lianbang Pharmaceutical [3][10]. - In 2025, BeiGene reported revenues of $5.343 billion, a 40% increase year-on-year, while adjusted net profits reached $917 million, marking a return to profitability [9][21]. - The report also notes that the average weight loss in the UBT251 trial was as high as 19.7% after 24 weeks, compared to a 2.0% loss in the placebo group [11][10]. Overseas Education - The vocational education sector is experiencing an upswing, with promising enrollment data, particularly for China Oriental Education [5][17]. - The education index saw a decline of 4.9% in the recent week, underperforming the Hang Seng National Enterprises Index by 2.1 percentage points [15]. - The report recommends focusing on China Oriental Education, which is expected to see accelerated enrollment growth due to its strategic adjustments in response to market demands [17][15].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 II. 已發行股份及/或庫存股份變動及足夠公眾持股量的確認 致：香港交易及結算所有限公司 公司名稱: 中滙集團控股有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00382 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,500,000,000 | USD | 0.01 | USD | | 15,000,000 | | 增加 / 減少 (-) | | | 500,000,000 | | | USD | | 5,000,000 | | 本月底結存 | | | 2,00 ...

附註： 第三份經修訂及重訂章程大綱及細則以英文撰寫。第三份經修訂及重訂章程大綱及細則的中 文譯本僅供參考。如英文版本與其中文譯本有任何歧義，概以英文版本為準。 開曼群島《公司法》 （經修訂） 股份有限公司 中滙集團控股有限公司 之 第三份經修訂及重訂 組織章程大綱及細則 （經於2026年1月26日通過 的特別決議案採納） 開曼群島《公司法》 （經修訂） 股份有限公司 中滙集團控股有限公司 之 第三份經修訂及重訂 組織章程大綱 （經於2026年1月26日通過 的特別決議案採納） 開曼群島《公司法》 （經修訂） 股份有限公司 中滙集團控股有限公司 之 第三份經修訂及重訂 組織章程大綱 （經於2026年1月26日通過 的特別決議案採納） 1 本公司名稱為中滙集團控股有限公司。 2 本公司之註冊辦事處設於Ogier Global (Cayman) Limited之辦事處，地址為89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands或董事會可能不時決定之 開曼群島其他地方。 3 本公司的成立目的並無限制，且本公司擁有全部權力及授權進行開曼群島法律 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 董事會宣佈，該通告所載的所有決議案已於股東週年大會上以投票表決方式 獲股東正式通過。 Edvantage Group Holdings Limited 中滙集團控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：0382） 於2026年1月26日舉行的 股東週年大會的投票結果 根據本公司於2024年1月19日於本公司股東特別大會上採納的股份獎勵計劃 （「2024年股份獎勵計劃」）及相關信託契據，本公司就2024年股份獎勵計劃委任 的信託受託人（「受託人」）不得就2024年股份獎勵計劃下的信託所持有的任何股 份行使任何投票權。因此，概無上述本公司尚未歸屬受獎勵股份的承授人將有 權就該等本公司受獎勵股份行使或促使受託人行使任何投票權。 因此，賦予股東權利出席股東週年大會並於會上投票贊成或反對各項決議案 的股份總數為1,199,066,722股；鑒於當中4,573,360股由受託人持有，具備可在股 東 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） 承董事會命 中滙集團控股有限公司 （股份代號：0382） 有關將於二零二六年一月二十六日（星期一）舉行之股東週年大會 適用的代表委任表格之澄清公告 茲 提 述 中 滙 集 團 控 股 有 限 公 司（「本公司」）隨 附 於 日 期 為 二 零 二 五 年 十 二 月 三十一日的通函（「該通函」）適用於二零二六年一月二十六日（星期一）舉行之 股東週年大會（「股東週年大會」）（及其任何續會或延會）的代表委任表格（「代 表委任表格」）。除另有指明外，本公告所用詞彙與股東週年大會通告、該通函 及代表委任表格所界定者具有相同涵義。 本公司注意到代表委任表格英文版不慎出現無意的筆誤，並謹此知會本公司 股東載於代表委任表格英文版的股東週年大會日期應為「26 January 2026」。 中文版代表委任表格並無上述文書錯誤，中文版代表委任表格之所有資訊及 內容均保持不變。 除上文所披露 ...

Group 1 - The core viewpoint of the article is that Guangdong Weiling Electric Motor Manufacturing Co., Ltd. has won a final victory in a patent infringement dispute against Tongda Company, which is expected to positively impact intellectual property protection in the home appliance industry [2][4]. - The Supreme People's Court upheld the first-instance judgment, ordering Tongda Company to immediately remove infringing products and compensate Weiling Electric for economic losses of 1.05 million yuan [2][4]. - Weiling Electric has identified multiple instances of infringement by Tongda Company, which manufactured and sold products without permission, significantly affecting Weiling's market share and operational order [4]. Group 2 - Weiling Electric, established in 1992, is a core subsidiary of Midea Group and recognized as a high-tech enterprise, specializing in the research and manufacturing of motors and their drive systems [4][5]. - The company has a production capacity exceeding 150 million units annually and operates five manufacturing bases across Guangdong and Anhui provinces, as well as Jiangsu [4]. - As of December 2025, Weiling Electric is expected to hold over 2,200 authorized patents, demonstrating its commitment to technological innovation and high-quality development in the home appliance sector [5].

Core Insights - The article emphasizes the growing importance of ESG (Environmental, Social, Governance) as a critical framework for assessing long-term corporate value and risk management in the context of sustainable development [1][8] - Zhonghui Group (0382.HK) was awarded the "Annual ESG Pioneer Award (Small and Medium Market Capitalization)" at the 2025 Gelonghui "Golden Award" for its effective balance between economic efficiency and social responsibility [1][8] Group 1: ESG Implementation in Education Sector - In the education sector, ESG is viewed as a "must-answer question" that directly impacts the quality of education, brand reputation, and sustainable development [3][4] - Zhonghui Group, as the largest private higher education and vocational training group in the Guangdong-Hong Kong-Macao Greater Bay Area, integrates "employment-oriented high-quality vocational education" into its long-term strategy, addressing the talent gap required for regional industrial upgrades [4] Group 2: Governance and Risk Management - The education industry requires high standards for governance structure, compliance, and risk management, which Zhonghui Group addresses by establishing an ESG governance system supervised by the board and a cross-departmental ESG working group [4][7] - ESG considerations are integrated into risk management and internal control frameworks, ensuring that strategies are effectively implemented at all institutional levels [4] Group 3: Environmental Initiatives - Zhonghui Group promotes "green campus" initiatives as a key aspect of educational modernization and sustainable development, focusing on energy conservation, resource management, and the use of green materials [4][5] Group 4: Employee Development and Social Responsibility - The company has developed a professional, equitable, and harmonious work environment, with over 270,000 hours of employee training planned for 2025, covering all staff levels [5] - Zhonghui Group has funded over 310,000 impoverished students with a total amount exceeding 80 million RMB and engaged in various community service activities, including over 25,000 hours of volunteer service in 2025 [6] Group 5: Compliance and Ethical Governance - The company emphasizes clean governance and campus safety, enhancing compliance awareness through anti-corruption training and ethical education [7] - Zhonghui Group actively promotes a culture of integrity within its institutions, aligning with national policies on compliance for private enterprises [7] Conclusion - The recognition of Zhonghui Group with the "Golden Award Annual ESG Pioneer Award" serves as authoritative validation of its ESG practices and reflects the capital market's acknowledgment of its long-term development model [8]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中滙集團控股有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00382 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 1,500,000,000 | USD | | 0.01 USD | | 15,000,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 1,500,000,000 | USD | | 0.01 USD | | 15,000,000 | 本月底法定 ...